How to Get Praluent (Alirocumab) in Washington State

What Is Praluent and Why Would a Washington Clinician Prescribe It?

Praluent is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more receptors on hepatocyte surfaces, which clears more LDL-C from the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond what maximally tolerated statin therapy provides [1].

The key ODYSSEY LONG TERM trial (N=2,341) demonstrated a 61 percent mean reduction in LDL-C from baseline at 24 weeks with alirocumab 150 mg every two weeks added to statin therapy, compared with a 0.8 percent change in the placebo group (P<0.0001) [2]. That LDL reduction translates into real cardiovascular benefit. ODYSSEY OUTCOMES (N=18,924) randomized patients with a recent acute coronary syndrome and showed that alirocumab reduced the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15 percent relative to placebo over a median 2.8-year follow-up (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [3].

Washington clinicians follow the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, which recommends PCSK9 inhibitor therapy for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [4]. Familial hypercholesterolemia patients with LDL-C at or above 100 mg/dL on maximally tolerated therapy are also guideline-supported candidates [4].

Who Qualifies for Praluent in Washington?

Clinical eligibility generally requires one of two documented conditions: established ASCVD with uncontrolled LDL-C, or familial hypercholesterolemia. Both must be confirmed before any prescriber, telehealth or in-person, can safely submit a prescription.

For ASCVD patients, most Washington payers require an LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy, with documentation of that statin trial in the medical record. For FH patients, the threshold is typically LDL-C at or above 100 mg/dL after a statin trial, or documented statin intolerance with two or more statin failures supported by creatine kinase (CK) or liver enzyme data [5]. The National Lipid Association defines statin intolerance as muscle or hepatic symptoms reproducible on re-challenge and resolving on discontinuation, with at least two statins tried [5].

Washington Medicaid (Apple Health) covers alirocumab under the preferred drug list with prior authorization for both indications. Eligibility reviewers look for a current lipid panel dated within 90 days, documentation of the statin trial, and a prescriber attestation of the diagnosis code (E78.01 for HeFH or Z82.49 for family history of ischemic heart disease combined with an active ASCVD code such as I25.10) [6].

Commercial insurers operating in Washington, including Premera Blue Cross, Regence BlueShield, and Kaiser Permanente Washington, apply similar criteria but may add a requirement for a recent visit note from a cardiologist or lipidologist rather than a primary care provider alone. Calling the member services number on your insurance card before your prescribing visit saves time.

How to Get a Praluent Prescription in Washington: Step by Step

Getting Praluent requires four sequential steps. Each has a defined timeline and specific documentation requirement.

Step 1. Order a fasting lipid panel. Your LDL-C must be measured after a 9-to-12-hour fast. A non-fasting panel is acceptable for initial screening, but most prior authorization (PA) forms require a fasting value. Quest Diagnostics and LabCorp both have draw sites throughout King, Pierce, Snohomish, Spokane, and Clark counties. Results are typically available within 24 to 48 hours [7].

Step 2. Schedule a prescribing visit. Any Washington-licensed MD, DO, NP, or PA with prescriptive authority may prescribe alirocumab. Washington's Nurse Practitioner Full Practice Authority (RCW 18.79.040) removed the supervising-physician requirement for NPs in 2023, so telehealth NPs operating independently can issue the prescription and sign the PA form without a collaborating physician [8]. A telehealth visit lasting 20 to 30 minutes is typically sufficient to review labs, confirm the diagnosis, and document statin history.

Step 3. Submit prior authorization. The prescriber's office submits PA to your insurer. Required documents almost universally include: the fasting lipid panel, a list of statins tried with doses and durations, any statin-intolerance lab work, the ICD-10 diagnosis code, and the prescriber's NPI. Washington Medicaid PA decisions are required within 72 hours for urgent requests and 14 calendar days for standard requests under WAC 182-501-0165 [9].

Step 4. Fill at a Washington-licensed pharmacy. Once PA is approved, the prescription can be filled at any Washington-licensed specialty pharmacy. Major specialty pharmacy networks including Walgreens Specialty, CVS Specialty, and Accredo serve the state. Praluent requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and is shipped in temperature-controlled packaging with cold packs. Expect 2 to 5 business days for shipping after the specialty pharmacy receives the PA approval and insurance coordination [10].

Telehealth Prescribing for Praluent in Washington

Washington is one of the more permissive states for telehealth prescribing of specialty medications. RCW 74.09.325 requires that commercial health plans and Medicaid reimburse telehealth services at parity with in-person visits, which means your telehealth consultation to initiate Praluent is billable under the same codes as an office visit [11].

The prescriber must hold an active Washington state license. A clinician licensed only in California or Oregon cannot prescribe for a Washington resident without holding a Washington license, even if the patient is physically in Washington during the video call. Washington participates in the Interstate Medical Licensure Compact (IMLC), which speeds multi-state licensing for physicians, but the Washington license itself is still required before prescribing [12].

Telehealth visits for Praluent initiation typically involve chart review of prior lab work, a structured medication history, and a cardiovascular risk assessment. Some telehealth platforms provide integrated lab ordering so you can complete the fasting lipid panel before your visit and have results loaded into the chart automatically. HealthRX clinicians reviewing alirocumab candidacy use a standardized intake that captures statin history, current ezetimibe use, CK levels, hepatic enzyme levels, and the most recent lipid fractionation panel.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states: "For patients with ASCVD who remain above LDL-C thresholds on maximally tolerated statin and ezetimibe, clinicians should initiate a PCSK9 inhibitor without further delay, as residual risk reduction is time-sensitive in post-ACS patients" [4]. That guidance applies equally to telehealth-initiated prescriptions.

Prior Authorization in Washington: What Documentation to Prepare

Prior authorization is the single most common reason for delays in Praluent access. Preparing the right paperwork before your prescribing visit cuts the approval timeline from two weeks to as few as three business days.

Washington commercial payers typically require all of the following in a single submission:

A fasting lipid panel dated within 90 days showing LDL-C at or above 70 mg/dL (ASCVD) or 100 mg/dL (FH). A pharmacy claims history or prescriber attestation listing every statin tried, the dose, and the duration. Statins tried for fewer than four weeks at each dose level may not satisfy payer requirements. Documentation of statin intolerance, if applicable, including a CK level drawn during symptomatic periods and liver function tests. The ICD-10-CM primary diagnosis code. A letter of medical necessity (LMN) signed by the prescriber, which most specialty pharmacies provide as a fillable template. Proof of a concurrent or recent cardiovascular event, such as hospital discharge summary, catheterization report, or echocardiogram, for ASCVD patients [13].

If the first PA is denied, Washington law gives you the right to an internal appeal within 180 days of the denial notice, and an external independent review if the internal appeal fails, under RCW 48.43.535 [14]. Denials based on "step therapy" requirements, meaning the insurer demands additional statin dose escalation before approving a PCSK9 inhibitor, can often be overturned when the prescriber documents that the current statin is already at maximum tolerated dose.

The Regeneron/Sanofi Praluent patient support program, called MyPraluent, offers a PA support service that contacts the insurer on the prescriber's behalf and tracks the case in real time. Washington residents with commercial insurance and income above Medicaid eligibility thresholds may also access the Praluent $0 co-pay card, which reduces out-of-pocket cost to zero for eligible patients [10].

Lab Work Required Before Starting Praluent in Washington

Labs needed before Praluent is prescribed serve two purposes: confirming eligibility and establishing a baseline for monitoring. No specific lab finding is a contraindication to alirocumab, but the baseline values anchor the PA submission and guide dose selection.

The minimum required panel includes a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C), a comprehensive metabolic panel (CMP) including liver enzymes (AST and ALT) and renal function, and a creatine kinase level if statin intolerance is part of the clinical picture [15]. Some prescribers add a lipoprotein(a) measurement. Elevated Lp(a) above 50 mg/dL or 125 nmol/L identifies a patient who may derive outsized benefit from LDL-C lowering, since Lp(a) is not directly reduced by PCSK9 inhibitors but high baseline Lp(a) predicts higher residual ASCVD risk [16].

Thyroid function (TSH) should be checked if secondary hypercholesterolemia is suspected, because hypothyroidism raises LDL-C independently and must be treated before attributing elevated LDL-C to primary dyslipidemia or FH [17]. Washington labs that accept standing physician orders include Quest Diagnostics (50-plus locations in Washington), LabCorp (40-plus locations), and Providence Laboratory Services for Providence Health Network patients in eastern Washington [7].

After starting alirocumab, a follow-up lipid panel at 8 to 12 weeks confirms the LDL-C response. If the response is less than 30 percent, the prescriber should evaluate adherence, injection technique, and whether dose escalation from 75 mg to 150 mg every two weeks (or switching to the 300 mg monthly formulation) is appropriate [1].

Pharmacies and Shipping: Getting Praluent Delivered in Washington

Praluent is classified as a specialty drug and is not stocked at standard retail pharmacies. Washington-licensed specialty pharmacies that carry alirocumab include Walgreens Specialty Pharmacy, CVS Specialty, Accredo (a subsidiary of Evernorth/Express Scripts), and AllianceRx Walgreens Pharmacy. Mail-order specialty pharmacies licensed to ship into Washington from out-of-state are also permitted, provided they hold a Washington out-of-state pharmacy license issued by the Washington State Department of Health [18].

503A compounding pharmacies in Washington may not compound alirocumab. PCSK9 inhibitors are not on the FDA's 503B bulk compounding list, and alirocumab is a commercially available FDA-approved biologic. Compounding a commercially available biologic outside an FDA-registered 503B outsourcing facility is prohibited under the Drug Quality and Security Act [19]. Any offer of "compounded alirocumab" from a Washington 503A pharmacy should be declined and reported to the Washington State Department of Health Pharmacy Quality Assurance Commission.

Shipping timelines from specialty pharmacies in Washington generally run two to five business days after PA approval and insurance coordination are complete. The drug ships refrigerated in insulated packaging validated for 96-hour temperature maintenance. If the auto-injector arrives warm or the cold packs are fully melted, do not use the pen. Contact the specialty pharmacy for a replacement; Praluent exposed to temperatures above 77 degrees Fahrenheit (25 degrees Celsius) for more than 30 days, or any exposure above 104 degrees Fahrenheit (40 degrees Celsius), should be discarded per the prescribing information [1].

Transferring a Praluent prescription from another state to Washington is straightforward if the prescriber is licensed in Washington or is willing to issue a new prescription under their Washington license. The specialty pharmacy performs a benefits investigation (BI) with your Washington insurance before processing. If you are moving to Washington from another state and your out-of-state prescriber is not licensed in Washington, a new prescribing visit with a Washington-licensed clinician is required. That visit can occur via telehealth within days of your arrival.

Dosing, Administration, and What to Expect Clinically

Alirocumab is self-administered by subcutaneous injection using a single-dose, pre-filled auto-injector pen. The starting dose for most ASCVD patients is 75 mg every two weeks, with dose escalation to 150 mg every two weeks at 8 to 12 weeks if the LDL-C response is insufficient [1]. For patients who prefer monthly dosing, 300 mg every four weeks is FDA-approved and produces equivalent lipid lowering in clinical trials [20].

Injection sites are the abdomen (at least two inches from the navel), the thigh, or the outer area of the upper arm. Rotate sites with each injection. The auto-injector should be left at room temperature for 30 to 40 minutes before injection. Do not shake the pen. Insert at a 90-degree angle and hold until the yellow indicator appears in the window of the device, confirming full dose delivery [1].

LDL-C begins falling within days of the first injection. Measurable reductions of 40 to 60 percent appear by week 4, with maximal effect at 8 to 12 weeks [2]. ODYSSEY OUTCOMES demonstrated that patients achieving LDL-C below 25 mg/dL on alirocumab did not experience any increase in neurocognitive adverse events, hemorrhagic stroke, or new-onset diabetes compared with those who achieved higher LDL-C values [3].

The most common adverse effect is injection-site reaction (erythema, itching, or bruising at the injection site), which occurred in 7.2 percent of alirocumab-treated patients versus 5.1 percent of placebo patients in ODYSSEY LONG TERM [2]. Nasopharyngitis was reported in 11.3 percent. Serious allergic reactions including hypersensitivity vasculitis and anaphylaxis have been reported rarely; patients should seek immediate care for throat tightness, hives, or difficulty breathing after injection [1].